Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine (GSK 357941A) [RIX 4414] in Healthy Infants.
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 21 Feb 2011 Primary endpoint 'Immunoglobulin-A-levels' has been met
- 20 Jan 2011 Results published in Vaccine.
- 01 Aug 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History